MAY 25, 2022 10:00 AM PDT

NYU Researchers Find CBD effectively Reduces Post Operative Pain

WRITTEN BY: Kerry Charron

An NYU research study found that a cannabidiol (CBD) tablet safely and effectively reduced post-operative pain. The tablet ORAVEXX was given to patients following minimally invasive rotator cuff surgery. The fast-release CBD tablet did not produce negative side effects like gastrointestinal distress or risks such as liver toxicity that sometimes accompany CBD oil use. Researchers in the Department of Orthopedic Surgery at New York University Langone Health recently presented the findings at the American Academy of Orthopaedic Surgeon’s 2022 Annual Meeting. 

Participants between the ages of 18 and 75 were placed into either a placebo group or a group receiving CBD. Participants were prescribed a low dose of the narcotic Percocet, and they were instructed to wean off the narcotic as soon as possible after surgery. Patients continued to take the placebo or CBD 3 times a day for two weeks.

Patients receiving CBD immediately following surgery experienced roughly 23% less pain as measured by the visual analog scale (VAS) pain score. Within two days after surgery, patients receiving CBD reported up to 25% improved pain levels compared to those receiving placebo. The study also indicated that patients taking 50mg of CBD reported lower pain and higher satisfaction with pain control compared to patients receiving placebo. 

An increasing body of research supports the use of CBD for pain management without the undesirable effects of pharmaceutical medications or tetrahydrocannabinol (THC).  

Lead investigator Michael J. Alaia, M.D. and associate professor in the Department of Orthopaedic Surgery, explained that CBD “...could be a new, inexpensive approach for delivering pain relief, and without the side effects of anti-inflammatory drugs like NSAIDs and addiction risks linked to opiates. Additionally, CBD has the benefit of pain relief without the psychotropic effects associated with THC or marijuana.” Expanding cannabinoid treatment options that provide therapeutic value without THC’s mind-altering influence is critical for addressing symptoms associated with many disorders.   

Cannabinoids interface with the human endocannabinoid system which is the set of receptors that are involved in a range of functions including memory, appetite, sleep, stress, and attention. CBD and THC differ in how they interact with receptors. CBD does not bind to the CB1 and CB2 receptors like THC does. In terms of targeting pain with CBD, future research and drug development will focus on how to develop and administer CBD ratio medical products that offer pain reduction and increased wellness without psychoactivity. 

ORAVEXX is designed and manufactured by the life sciences company Orcosa Inc. It is considered non-addictive and safe. NYU Langone recently started another study on ORAVEXX treatments for osteoarthritis patients. Multiple phase 2 studies will evaluate the drug’s efficacy for other acute and chronic pain management issues and assess the role of CBD on inflammation.

Sources: 


Eureka Science Alerts, NYU Langone Health

 

About the Author
BA and MA in English, MPS in Human Relations, and Ed.D. in Higher Education Administration
Kerry Charron writes about medical cannabis research. She has experience working in a Florida cultivation center and has participated in advocacy efforts for medical cannabis.
You May Also Like
NOV 30, 2021
Cannabis Sciences
To Trust or Not to Trust the Process: Bioreactive Chemical Variation in Cannabis Extracts Based on Extraction Method
NOV 30, 2021
To Trust or Not to Trust the Process: Bioreactive Chemical Variation in Cannabis Extracts Based on Extraction Method
With cannabis legislation becoming increasingly less restrictive over the past 20 years, consumers have found themselves ...
JAN 14, 2022
Cannabis Sciences
Myrcene: The Power Terpene
JAN 14, 2022
Myrcene: The Power Terpene
A recent review published in Frontiers in Nutrition highlighted the terpene myrcene’s phytotherapeutic profile and ...
JAN 21, 2022
Cannabis Sciences
CBD inhalant effective in reducing glioblastoma tumors
JAN 21, 2022
CBD inhalant effective in reducing glioblastoma tumors
Researchers at Augusta University found that hat CBD inhalant can alter the lung microenvironment and subsequently inhib ...
MAR 07, 2022
Cannabis Sciences
Cannabis compound CBN supports mitochondrial function
MAR 07, 2022
Cannabis compound CBN supports mitochondrial function
Cannabinol (CBN) has been established as a neuroprotective, but a recent study reveals just how CBN protects mitochondri ...
APR 14, 2022
Health & Medicine
CBD and THC are Safe Supplements to Opioid Treatment
APR 14, 2022
CBD and THC are Safe Supplements to Opioid Treatment
A recent study found that it is safe and effective to use cannabidiol (CBD),∆9-tetrahydrocannabinol (THC), and CBD/THC m ...
MAY 26, 2022
Cannabis Sciences
Cannabis Crystal Polymorphism
MAY 26, 2022
Cannabis Crystal Polymorphism
A new published commentary in the Journal of Cannabis Research indicated that cannabis crystallinity may determine level ...
Loading Comments...